Palladio Biosciences
5 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who Completed Study PA-ADPKD-303 (NCT05208866) | Palladio Biosciences | 2022-02-10 |
| Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (NCT04064346) | Palladio Biosciences | 2021-10-28 |
| Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease (NCT04152837) | Palladio Biosciences | 2020-09-02 |
| The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (NCT03487913) | Palladio Biosciences | 2018-09-14 |
| Lixivaptan in a Single Subject With Intractable Pain Due to Polycystic Kidney Disease (NCT03717181) | Palladio Biosciences |
Track Palladio Biosciences automatically
Every clearance here is in the API, with alerts when new ones post.